V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003372 | 210008976 | 1.69 | 73 | null | 2019-03-04 | 2019-03-09 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100784396 |
| 210003374 | 210008977 | 1.56 | 77 | Neo-adjuvant (N) | 2018-12-23 | 2019-03-10 | null | 02 | N | EC | 100104750 |
| 210003375 | 210008978 | null | null | Adjuvant (A) | 2018-08-16 | 2018-09-07 | Letrozole + Palbociclib | N | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101478107 |
| 210003380 | 210008982 | 1.71 | 76.1 | Neo-adjuvant (N) | 2018-08-22 | 2018-09-04 | Paclitaxel+Trastuzumab wkly Maint | null | N | PACLITAXEL + TRASTUZUMAB | 100381088 |
| 210003381 | 210008983 | null | 74.9 | Palliative (P) | 2018-05-21 | 2018-06-03 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101838247 |
| 210003388 | 210008986 | 1.58 | 89.1 | Palliative (P) | null | 2017-06-13 | PACLITAXEL + TRASTUZUMAB | 02 | N | PACLITAXEL + TRASTUZUMAB | 101361613 |
| 210003389 | 210008987 | 1.68 | 65.2 | Neo-adjuvant (N) | 2016-12-22 | 2017-03-30 | null | null | N | FEC | 100808778 |
| 210003391 | 210008988 | 1.6 | 56 | Neo-adjuvant (N) | 2018-11-29 | 2018-12-13 | null | null | N | LETROZOLE + PALBOCICLIB | 100277944 |
| 210003393 | 210008990 | 1.59 | 67.7 | null | null | 2016-12-21 | null | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101536249 |
| 210003395 | 210008991 | 1.67 | 68.5 | Neo-adjuvant (N) | null | 2016-09-24 | Pertuzumab (Maintenance) | 02 | N | PERTUZUMAB | 100942361 |
| 210003400 | 210008993 | null | 97.3 | Adjuvant (A) | null | 2018-03-11 | Pertuzumab + Trastuzumab IV | 02 | N | PERTUZUMAB + TRASTUZUMAB | 101441451 |
| 210003402 | 210008995 | 1.66 | 102.6 | null | 2019-07-30 | 2019-08-29 | TCH (21 day Trastuzumab) Maint | 01 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101799200 |
| 210003403 | 210008996 | 1.54 | 62.4 | null | null | 2016-09-06 | Carboplatin AUC 6 - 10 | 02 | null | CARBOPLATIN | 100277269 |
| 210003404 | 210008997 | 1.69 | 50 | null | 2018-06-18 | 2018-07-02 | Carboplatin + Docetaxel | 02 | null | LETROZOLE + PALBOCICLIB | 100247433 |
| 210003411 | 210009001 | 1.76 | 106.4 | Adjuvant (A) | 2020-05-30 | 2020-06-07 | null | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101557115 |
| 210003412 | 210009002 | 1.61 | 0 | Curative (C) | 2013-04-17 | 2015-07-24 | Cyclophosphamide + Docetaxel | N | N | TRASTUZUMAB EMTANSINE | 101673507 |
| 210003414 | 210009003 | 1.52 | null | null | 2017-01-10 | 2017-03-24 | Neratinib | null | null | NERATINIB | 101470279 |
| 210003416 | 210009005 | 1.58 | 74 | Palliative (P) | null | 2019-11-26 | ABEMACICLIB + FULVESTRANT | null | N | LETROZOLE + PALBOCICLIB | 101247313 |
| 210003417 | 210009006 | 1.61 | 90 | Adjuvant (A) | 2017-08-03 | 2017-08-11 | Palbociclib | null | N | LETROZOLE + PALBOCICLIB | 100638452 |
| 210003418 | 210009007 | 1.53 | 0 | Neo-adjuvant (N) | 2016-09-30 | 2016-10-28 | null | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100692735 |
| 210003422 | 210009009 | 1.6 | 62.5 | Adjuvant (A) | null | 2016-10-30 | Trial Unspecified | N | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100481615 |
| 210003423 | 210009010 | 1.41 | 64.9 | Palliative (P) | 2019-03-06 | 2019-03-20 | null | null | N | TRASTUZUMAB EMTANSINE | 100293313 |
| 210003424 | 210009011 | 1.64 | 72.8 | null | 2019-03-11 | 2019-03-26 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100219252 |
| 210003426 | 210009013 | null | 58 | Neo-adjuvant (N) | 2018-05-10 | 2018-05-24 | null | null | N | LETROZOLE + PALBOCICLIB | 101846842 |
| 210003428 | 210009015 | 1.78 | 69.7 | null | null | 2020-10-11 | Trial Unspecified | null | null | CONCEPT TRIAL | 100592120 |
| 210003429 | 210009016 | null | 59 | null | null | 2016-12-01 | FEC 60 or 75 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100147183 |
| 210003430 | 210009017 | 1.68 | null | Adjuvant (A) | 2017-08-12 | 2017-11-23 | Capecitabine | N | N | CAPECITABINE | 100944278 |
| 210003431 | 210009018 | 1.6 | 78.5 | Palliative (P) | null | 2020-01-10 | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL + Pertuzumab + Trastuzumab | N | null | CAPECITABINE | 100614570 |
| 210003433 | 210009020 | 1.66 | null | null | 2015-07-27 | 2015-10-25 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 101385512 |
| 210003435 | 210009022 | 1.68 | 76.5 | null | null | 2018-07-04 | PERTUZUMAB + TRASTUZUMAB | null | null | PERTUZUMAB + TRASTUZUMAB | 101535177 |
| 210003439 | 210009025 | 1.62 | 72.9 | Adjuvant (A) | 2019-08-30 | 2019-08-30 | Capecitabine | null | N | CAPECITABINE | 100457558 |
| 210003442 | 210009028 | null | 71.35 | null | 2017-07-16 | 2017-07-19 | Pertuzumab (Loading) | 02 | null | PERTUZUMAB | 101448039 |
| 210003443 | 210009029 | 1.75 | 69.6 | Neo-adjuvant (N) | 2018-05-30 | 2018-06-01 | null | N | N | LETROZOLE + PALBOCICLIB | 100181980 |
| 210003449 | 210009033 | 1.63 | 68.9 | null | 2020-11-17 | 2020-11-24 | null | 02 | null | FULVESTRANT + RIBOCICLIB | 100247069 |
| 210003452 | 210009036 | 1.69 | 54.55 | Adjuvant (A) | 2017-05-10 | 2017-05-10 | FEC | null | N | EC | 101775997 |
| 210003455 | 210009038 | 1.61 | 56.7 | null | 2017-07-27 | 2018-06-06 | null | null | null | FULVESTRANT + PALBOCICLIB | 101287174 |
| 210003457 | 210009039 | 1.66 | 78 | Neo-adjuvant (N) | 2019-10-14 | 2019-10-14 | null | null | N | FEC | 100233095 |
| 210003458 | 210009040 | 1.6 | 91.5 | Palliative (P) | 2017-12-21 | 2017-12-27 | Atezolizumab | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100518706 |
| 210003460 | 210009041 | 1.62 | 109.9 | Adjuvant (A) | null | 2019-01-22 | Capecitabine | null | N | CAPECITABINE | 101755372 |
| 210003463 | 210009043 | 1.58 | 57.1 | null | 2018-12-20 | 2021-09-25 | null | 02 | null | PACLITAXEL + TRASTUZUMAB | 100494571 |
| 210003464 | 210009044 | null | null | Neo-adjuvant (N) | 2018-04-10 | 2018-06-18 | ROSCO Trial | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 101854779 |
| 210003465 | 210009045 | 1.63 | 81 | null | 2020-12-03 | 2021-12-11 | Capecitabine | 02 | null | CAPECITABINE | 101197541 |
| 210003469 | 210009049 | 1.85 | 70.8 | Curative (C) | null | 2018-07-09 | Fulvestrant + Palbociclib | N | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100346754 |
| 210003470 | 210009050 | 1.65 | 89 | null | 2018-02-01 | 2018-02-08 | Capecitabine | 02 | null | CAPECITABINE | 101645975 |
| 210003471 | 210009051 | 0 | 79.4 | Palliative (P) | 2017-01-17 | 2017-04-03 | Doce + Pertuzumab + Trastuz IV Load | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100558104 |
| 210003473 | 210009053 | 1.46 | 0 | null | null | 2017-04-10 | null | N | null | TRASTUZUMAB EMTANSINE | 100851270 |
| 210003479 | 210009057 | 1.63 | 63.9 | Adjuvant (A) | 2016-07-06 | 2016-07-13 | TCH (21 day Trastuzumab) Maint | 02 | N | PALBOCICLIB | 101047420 |
| 210003481 | 210009058 | 1.69 | 86 | null | 2016-11-27 | 2016-12-08 | EC | 02 | null | EC | 101133255 |
| 210003484 | 210009060 | 1.75 | 0 | null | 2018-03-05 | 2018-03-05 | Cyclophosphamide + Docetaxel | N | null | NAB-PACLITAXEL | 101074495 |
| 210003485 | 210009061 | 1.47 | 59.3 | Palliative (P) | 2019-06-18 | 2019-07-02 | PERTUZUMAB + TRASTUZUMAB | 01 | N | PERTUZUMAB + TRASTUZUMAB | 101283748 |